Explore 3 Stock Ideas & Industry Insights Download Free Report

Claritev Corporation

Healthcare US CTEV

25.84USD
-1.73(6.27%)

Last update at 2026-06-05T20:00:00Z

Day Range

25.3427.14
LowHigh

52 Week Range

12.0474.07
LowHigh

Fundamentals

  • Previous Close 27.57
  • Market Cap380.91M
  • Volume70199
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA535.44M
  • Revenue TTM965.41M
  • Revenue Per Share TTM58.74
  • Gross Profit TTM 712.00M
  • Diluted EPS TTM-17.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -373.07800M -1770.71200M -107.06000M -560.74300M 135.45M
Minority interest 0.00000M 0.00000M 0.00000M - -
Net income -284.28200M -1645.83100M -91.69700M -572.91200M 102.08M
Selling general administrative 221.52M 160.22M 135.99M 132.14M 151.09M
Selling and marketing expenses - - - - -
Gross profit 266.58M 691.22M 726.06M 875.62M 942.31M
Reconciled depreciation 448.45M 436.44M 425.79M 415.66M 412.06M
Ebit 26.99M -1444.34100M 226.15M -257.34200M 402.93M
Ebitda 475.44M -1007.90400M 651.93M 158.32M 814.99M
Depreciation and amortization 448.45M 436.44M 425.79M 415.66M 412.06M
Non operating income net other - - - - -
Operating income 45.06M -1389.93100M 161.98M -362.73200M 386.12M
Other operating expenses 920.36M 2320.55M 799.54M 1442.45M 731.48M
Interest expense 400.07M 326.37M 333.21M 303.40M 267.48M
Tax provision -88.79600M -124.88100M -15.36300M 12.17M 33.37M
Interest income 1.56M 3.13M 8.23M 3.50M 0.03M
Net interest income -390.46100M -323.24100M -324.97500M -299.90100M -267.44500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -88.79600M -124.88100M -15.36300M 12.17M 33.37M
Total revenue 965.41M 930.62M 961.52M 1079.72M 1117.60M
Total operating expenses 221.52M 2081.15M 564.07M 1238.35M 556.19M
Cost of revenue 698.84M 239.40M 235.47M 204.10M 175.29M
Total other income expense net -418.13600M -380.78100M -269.04200M -198.01100M -250.66700M
Discontinued operations - - - - -
Net income from continuing ops -284.28200M -1645.83100M -91.69700M -572.91200M 102.08M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4888.46M 5150.83M 6964.69M 7371.10M 8220.41M
Intangible assets 1884.60M 2226.32M 2633.21M 2940.20M 3285.04M
Earning assets - - - - -
Other current assets 69.38M 47.06M 37.29M 33.78M 34.02M
Total liab 5055.63M 5066.81M 5255.56M 5580.56M 5875.74M
Total stockholder equity -173.90000M 84.02M 1709.12M 1790.54M 2344.67M
Deferred long term liab - - - - -
Other current liab 181.50M 109.83M 129.11M 142.94M 108.77M
Common stock 0.00200M 0.00200M 0.00200M 0.07M 0.07M
Capital stock 0.00200M 0.00200M 0.00200M 0.07M 0.07M
Retained earnings -2429.42000M -2145.13800M -499.30700M -347.80000M 225.11M
Other liab - - - - -
Good will 2405.85M 2403.14M 3829.00M 3705.20M 4363.07M
Other assets - - - - -
Cash 16.81M 16.85M 71.55M 334.05M 185.33M
Cash and equivalents - - - - -
Total current liabilities 261.36M 213.79M 166.74M 175.84M 141.91M
Current deferred revenue - - - - -
Net debt 4615.49M 4524.37M 4496.35M 4448.32M 4740.67M
Short term debt 19.39M 17.64M 18.04M 19.61M 20.13M
Short long term debt 14.69M 13.25M 13.25M 13.25M 13.25M
Short long term debt total 4632.31M 4541.22M 4567.90M 4782.36M 4926.00M
Other stockholder equity 2259.69M 2234.22M 2220.21M 2138.28M 2119.49M
Property plant equipment - - - - -
Total current assets 224.37M 175.51M 193.59M 446.74M 319.26M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 138.18M 111.61M 84.75M 78.91M 99.91M
Long term debt 4580.44M 4509.73M 4532.73M 4741.86M 4879.14M
Inventory - - - - -
Accounts payable 60.46M 86.33M 19.59M 13.29M 13.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.17200M -5.06300M -11.77800M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 33.34M 22.10M 21.78M 21.89M 9.70M
Deferred long term asset charges - - - - -
Non current assets total 4664.09M 4975.31M 6771.09M 6924.37M 7901.15M
Capital lease obligations 20.94M 18.24M 21.92M 27.26M 33.61M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 13.33M -118.12300M -249.79200M -104.44600M -228.37900M
Change to liabilities - - - - -
Total cashflows from investing activities -121.01800M -118.12300M -249.79200M -104.44600M -228.37900M
Net borrowings 8.98M -28.06900M -165.81800M -113.27500M -10.89500M
Total cash from financing activities 2.36M -41.31500M -180.99300M -115.73800M -114.68400M
Change to operating activities - - - - -
Net income -284.28200M -1645.83100M -91.69700M -572.91200M 102.08M
Change in cash -1.33100M -51.82200M -259.06500M 152.18M 61.62M
Begin period cash flow 29.67M 81.49M 340.56M 188.38M 126.75M
End period cash flow 28.34M 29.67M 81.49M 340.56M 188.38M
Total cash from operating activities 117.32M 107.62M 171.72M 372.36M 404.69M
Issuance of capital stock - - - - -
Depreciation 445.43M 436.44M 425.79M 415.66M 424.32M
Other cashflows from investing activities -7.41700M - - - 5.64M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -26.57000M -13.20000M 4.40M 21.00M -33.82600M
Sale purchase of stock 0.00000M -10.37000M -15.21800M -99.99900M -103.78900M
Other cashflows from financing activities -4.09500M -2.87600M -0.46500M -2.46300M -3.78900M
Change to netincome - - - - -
Capital expenditures 129.60M 118.12M 108.85M 89.73M 84.59M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -28.86600M -13.66900M -21.90800M 55.34M -46.67800M
Stock based compensation 27.82M 26.64M 18.02M 16.74M 18.01M
Other non cash items 85.73M 1502.04M -44.41900M 571.92M -93.04200M
Free cash flow -12.27700M -10.50700M 62.87M 282.63M 320.10M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CTEV
Claritev Corporation
-1.73 6.27% 25.84 - - 0.39 0.23 5.13 10.59
VEEV
Veeva Systems Inc Class A
-5.99 3.35% 172.61 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc
- -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc
0.08 1.68% 4.84 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock
- -% 57.40 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

Profile

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.

Claritev Corporation

7900 Tysons One Place, McLean, VA, United States, 22102

Key Executives

Name Title Year Born
Mr. Travis S. Dalton CEO, President & Chairman 1971
Mr. Douglas M. Garis Executive VP & CFO 1985
Mr. Jerome W. Hogge III Executive VP & COO 1966
Mr. Michael C. Kim Executive VP & Chief Digital Officer 1966
Ms. Tiffani D. Misencik Senior VP & Chief Growth Officer 1973
Mr. Brock Albinson Senior VP & Chief Accounting Officer 1975
Mr. Jason Wong Senior Vice President of Treasury & Investor Relations 1971
Ms. Tara A. O'Neil Senior VP & Chief Legal Officer 1966
Ms. Kristen Lambert-Kennedy Chief Compliance & Chief Privacy Officer NA
Ms. Melissa Humphrey Senior Vice President of Marketing & Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.